13. Krasner, J.. Juchau (28) , is increased by A 11. Nevertheless, the presence of renal sodium wastage cannot be explained only by the high A I1 levels which are constant in this syndrome. A deficient Na-K-ATPase activity is postulated in such cases.
The highest levels of PRA and A 11 are observed in Bartter's syndrome (1, 2) . However, the mechanism of excessive secretion and their role in pathophysiology is not yet clearly understood. A 1 1 has been shown to stimulate aldosterone secretion and to suppress renin secretion in Bartter's syndrome (10, 13). Modlinger et al. (20) have observed an increase in renal sodium excretion under A 11 infusion in one patient.
Two types of Bartter's syndrome can be described in childhood according to the presence or the absence of renal sodium wastage (28) . In order to elucidate the regulation of the renin-aldosterone axis and the role of A I1 on urinary sodium excretion In these two types of Bartter's syndrome, five patients were investigated: two had renal sodium wastage and three were without renal sodium loss. The effects of sodium restriction and of A 11 infusion on PRA, aldosterone secretion, and renal excretion of sodium and potassium were studied.
MATERIALS AND METHODS

CASE REPORTS
Patient I . BP, a boy born March 14, 1954 , was admitted to Hbpital E. Herriot at the age of 5'/2 years because of polyuria, polydipsia, and growth retardation. He had a normal birth (birth weight 4,500 g) after a full term pregnancy. Physical examination was normal with normal weight (18,800 kg) but short stature (I m; 2 SD). Blood pressure was 100/70 mm Hg.
On admission, serum potassium was 2.3 mEq/liter. Subsequent determinations revealed persistent hypokalemia (1.9-3.5 mEq/ liter) with metabolic alkalosis. Serum sodium was 136 mEq/liter and urea nitrogen 30 mg/ 100 ml. Urine volume varied from 1,000 to 2,200 ml. Urinary excretion of potassium was found to be between 17 and 75 mEq/24 hr. Proteinuria was detected (2 g/24 hr) with a tubular electrophoretic pattern. Urine cultures were negative. Urine was negative for glucose and amino acid chromatography was normal. Creatinine clearance was 130 rnl/min/1.73 m2. Maximum urinary concentration after 12 hr of water restriction was 602 mOsm/kg H 2 0 . Impaired urinary acidification was observed. Bone marrow and slit lamp examination were normal.
High basal PRA (1,142 ng/liter/min; normal for age 54 * 10) and aldosterone secretion rate (427 pg/24 hr) were found. Renal biopsy showed enlargement of the juxtaglomerular apparatus with typical hypokalemic features. Exchangeable sodium was low: 38.24 mEq/ kg body weight (normal for age 45-55 mEq/kg); exchangeable potassium was also low: 24.5 mEq/kg of lean mass (normal for age 40 mEq/kg).
The patient was treated with chloride sodium (6-20 g/24 hr) and chloride potassium (7-20 g/24 hr). Spironolactones (300 mg/24 h) were given from 8'0/;2 to 18 years of age with a transient increase in serum potassium.
At the age of 10 years Cushing's syndrome was discovered; it was successfully treated with aminogluthetimide (750 mg-2.25 g/24 hr) for 8 years and the cortisol secretion rate dropped from 40 to 21 mg/m2 24 hr (normal values l l 5 mg/m2/24 hr). Two episodes of rickets with hypophosphoremia (2.3-2.9 mg/100 ml) were treated with 30 mg vitamin D,. The patient was 19% years old when A I1 infusion was performed; spironolactone and aminogluthetimide were discontinued after 1 ?h years. A detailed description of this case has been reported (24) .
Patient I I . AT is a boy born November 25, 1959. He was admitted for the first time to Hbpital Debrousse for hypotrophy, polyuria, and polydipsia at the age of 13% years.
Physical examination showed only low weight (27,400 kg; -2 SD) and short stature (I34 cm; -3 SD) Blood pressure was 100/70 mm Hg.
On admission, serum potassium was 2.8 mEq/liter and subsequent hypokalemia was recorded (1.8-3.6 mEq/liter). It was associated with hyperkaluria (25-68 mEq/24 hr). Serum sodium was 135 mEq/liter, chloride 98 mEq/liter, carbon dioxide 24 mEq/liter. Urine volume was between 3.5 and 5 liters/day. Urine was negative for protein and glucose and amino acids chromatography was normal. Creatinine clearence was 81 ml/min/I .73 m2. Maximum urinary osmolality after 12 hr of water restriction was 333 mOsm/kg H 2 0 . Urinary acidification was normal. Further investigations showed high PRA (186 ng/liter/min; normal for age 35 12) and aldosterone secretion rate (151 pg/24 hr). Juxtaglomerular hyperplasia was observed on renal biopsy. Bone marrow and slit lamp examination were normal. Bone x-rays and intravenous pyelogram were normal. Treatment was carried out with potassium chloride (10 g/day) and spironolactones (200 mg/day) without any change in kalemia.
Patient I I I . JS was born May 13, 1969 . She weighed 1,700 g at the 32nd week of an uneventful pregnancy. She was admitted to Hapita1 Debrousse for the first time at the age of 3 x 2 years because of persistent vomiting. Physical examination showed only an emaciated girl with low weight (10,500 kg; -3 SD) and growth retardation (85 cm; -3 SD). Blood pressure was 85/60 mm Hg.
On admission, transient hypoglycemia (23 mg/100 ml) was observed, but all of the endocrinologic and metabolic investigations were normal. Hypokalemia (1.8-3.5 mEq/liter) was associated with hyperkaluria (15-32 mg/24 hr). Serum sodium was 140 mEq/liter, chloride 92 mEq/liter, carbon dioxide 22 mEq/liter, and urea nitrogen 33 mg/100 ml. Urine volume varied from 200 to 500 ml/day. Proteinuria (0.80 g/24 hr) showed a tubular electrophoretic pattern. Urines cultures were negative. No glycosuria was detected and amino acid chromatography was normal. Creatinine clearance was 118 ml/min/ 1.73 m2. Maximum urinary concentration after 12 hr of water restriction was 1,500 mOsm/kg H,O. No impaired urinary acidification was detected. Bone x-rays and intravenous pyelogram were normal. Bone marrow and slit lamp examination were normal. Further investigations showed high PRA (483 ng/liter/min; normal for age l l l * 39); aldosterone secretion rate was at the lower limit of normal range (58.5 pg/24 hr). Renal biopsy revealed typical juxtaglomerular hyperplasia. Treatment was carried out with potassium gluconate (7 g/day) and triamterene (100 mg/day). However, no change in kalemia was observed.
Patient IV. HN was born May 19, 1960 . Diabetes mellitus was discovered at the age of 10% years and was satisfactorily treated with long acting insulin with doses between 26 and 42 U/day. Persistent hypokalemia (2.2-2.8 mEq/liter) was discovered at the age of 132/;2 years by systematic investigations. His physical examination was normal (weight 35 kg, height 137 cm). Blood pressure was 90150 mm Hg. Serum sodium was 142 mEq/liter, chloride 97 mEq/liter, carbon dioxide 28 mEq/liter, urea nitrogen 38 mg/ 100 ml, and glucose 76-118 mg/ 100 ml. Urinary protein (0.7 g/24 hr) showed typical tubular electrophoretic pattern. No amino acid abnormalities were detected. Urinary cultures were negative. Urinary glucose was found to be between 8.52 and 42 g/day. Hyperkaluria (35-58 mEq/24 hr) was found in spite of hypokalemia. Bone x-rays and intravenous pyelogram were normal. Further investigations showed high PRA (268 ng/liter/min; normal for age 35 + 7) and high plasma aldosterone (288 pg/ml). Fig. 2 . Effect of angiotensin I 1 (A II) infusion on plasma renin activity (P.R.A.) plasma aldosterone, serum and urinary sodium and potassium in one patient without renal salt loss. IVA: patient I V on a normal diet; IVB: patient IV on a salt-restricted diet (Na < 10 mEq/24 hr).
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Creatinine clearence was 132 ml/min/1.73 m2. Bone marrow and slit lamp examination were normal. In addition to insulin, treatment included potassium gluconate (12 g/day), triamterene (300 mg/day), and NaCl (10 g/day). No change in serum potassium and PRA could be observed.
Patient V. CG was born October 22, 1968. She was first admitted to Hbpital E. Herriot at the age of 6 years because of vomiting and growth retardation. Physical examination showed only short stature (97 cm; -3.5 SD) with low weight (12 kg; -3 SD). Blood pressure was 90150 mm Hg. Serum potassium was 1.6 mEq/liter on admission; subsequent hypokalemia (1.8-3.1 mEq/ liter) and hyperkaluria (36-45 mEq/liter) were detected. Serum sodium was 140 mEq'/liter, chloride 82 mEq/liter, carbon dioxide 20.5 mEq/liter, urea nitrogen, 27 mg/100 ml. Urine volume was 1,000 m1/24 hr. Urine cultures were negative and no urine glucose was detected; amino acid chromatography was normal.
Proteinuria (0.10 g/day) showed mixed glomerular and tubular pattern at immunoelectrophoresis. Creatinine clearence was 118 ml/min/1.73 m2. Maximum urinary osmolality after 12 hr of water restriction was 768 mOsm/kg H,O. Further investigations showed high PRA (952 ng/liter/min; normal for age 54 * 10) and high plasma aldosterone level (330 pg/ml). Juxtaglomerular hyperplasia was observed on renal biopsy. Bone marrow and slit lamp examination were normal. Exchangeable sodium was 45' mEq/kg body weight (normal for age 45-55 mEq/kg body wt). Treatment was carried out with amiloride (5 mg/day). Serum potassium and PRA remained at abnormal levels.
MEASUREMENTS AND PROCEDURES
T I M E man
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These were all carried out before any treatment was started or -30 o 30 when the treatments were discontinued for at least 2 weeks. Fig. 3 . Effect of angiotensin I1 (A II) infusion on plasma and urinary Informed consent of the parents was obtained in all cases. sodium in patient III.
Aldosterone secretion rate was measured by gas chromatography with a modified method of Flood et al. (1 1) . Venous samples of PRA and plasma aldosterone assays were taken in the morning (8-9 AM), the patient resting recumbent in bed for at least a few hours. Blood was directly collected in tubes containing EDTA and kept on ice. After centrifugation at +4', plasma was immediately separated and frozen at -20'. PRA (27) and plasma aldosterone (3) were determined by radioimmunoassay. Normal results of PRA for age have been reported previously (25) . Sodium restriction was performed for at least 5 days with a controlled diet providing less than 10 mEq of sodium every day. Dietary intake of sodium was estimated by standardized tables (9) . Serum and urinary electrolytes were determined by flame photometry. A I1 infusion was based on the procedure of Kaplan and Silah (17) . The effect of a suprapressive rate of A I1 was tested on PRA and plasma aldosterone. At the same time, the effect of A 11 in 5% dextrose on serum and urinary sodium and potassium was compared with a previous infusion of only 5% dextrose. First, as in the procedure of Modlinger et al. (20) , A 11 infusion was performed for 30 rnin (patients II and III). It was then performed for 180 rnin in the other patients. Therefore, 5% dextrose in water was first infused at the rate of 0.5 ml/min for 60 min in all the patients but one (patient II). Then, hypertensin (Ciba) in 5% dextrose was infused at the same rate and at concentration of 80 ng/kg/min for 30-180 minutes. These infusions were all performed in early morning on recumbent patients. Blood and urinary samples were collected every 15 min in patient II and every 30 min in the other patients. Table 1 shows the effect of sodium restriction in the five patients. PRA and aldosterone secretion increased in all the patients. Renal sodium wastage in spite of increased aldosterone secretion was detected only in patients I and II .   ANGIOTENSIN 11 INFUSION (FIGS. 1-4) No change of blood pressure was observed in any case. A I1 induced a sharp decrease in PRA in the patients who could be studied. When patient I V was on a sodium-restricted diet (Fig. 3) , a similar decrease in PRA was observed but the minimal PRA was was still higher. In no case could a normal PRA be obtained. A I1 infusion always resulted in a marked increase in plasma aldosterone levels.
RESULTS
SODIUM RESTRICTION
An immediate and dramatic increase in urinary sodium excretion was detected in the patients with renal sodium wastage (Fig.  1) . This increase was particularly important during the first 30 min in patient I. In patient II, it occurred in spite of increased plasma aldosterone. The other patients showed no similar increase in urinary sodium excretion. Moreover, a reduction of fractional sodium excretion was observed in patient V (Fig. 4) . No change of sodium excretion was obtained in patient I V when he was on a sodium-restricted diet (Fig. 2, IVB) . Urinary potassium excretion was similar to the sodium excretion all patients. A dissociation was of sodium balance in patients IV and V since exchangeable sodium observed only when patient IV was on a sodium-restricted diet. was normal in patient V , since sodium restriction did not result in The increase in urinary potassium occurred without any signifi-renal sodium wastage, and because A I1 infusion induced no renal cant change in urinary sodium; at the same time, an increase in sodium wastage. The only persistent abnormality which could be plasma aldosterone was observed. observed in our patients was hypokalemia, which is known to Blood sodium and potassium remained unchanged during A I1 induce high PRA levels (6, 26) . Therefore, we strongly support the infusion.
view of Godard et al. (13) that potassium perse could play a role in the pathogenesis of renin hypersecretion independent of any
DISCUSSION
The pathogenesis of renin hypersecretion in Bartter's syndrome is not known. The primary vascular insensitivity to A I1 proposed by Bartter (I, 2) is not yet accepted (7, 14, 29) . Then Brackett et al. (5) suggested the existence of an autonomous secretion of renin. However, sodium restriction results in normal increase in PRA and aldosterone secretion. On the other hand, a sharp decrease of PRA and plasma aldosterone under sodium infusion has already been described in parienr I (20) . Therefore, there is a normal regulation of the renin-aldosterone axis by sodium restriction or infusion. It is known that A I1 has a suppressive effect on renin secretion (4). When A I1 was infused into our patients, this feedback effect was found. This result agrees with previous similar investigations (10, 13) , but our results show that this feedback is found in patients with renal sodium wastage as well as in patients without sodium wastage. This decrease of PRA with A I1 infusion was observed even when patient IV was on a salt-restricted diet. Therefore, this study demonstrates that the secretion of renin is not autonomous in both types of Bartter's syndrome.
Despite the normal regulation of the renin-aldosterone axis, a normal PRA could not be obtained under A 11 infusion. The persistent high PRA value could not be explained by a disturbance change in sodium balance.
Infusions of high concentrations of A I1 are known to induce a natriuresis. Modlinger et al. (20) observed increased urinary sodium excretion when A 11 was infused for 30 min in one case of Bartter's syndrome with renal sodium loss. The result was confirmed only in our patients with sodium wastage. In this condition, increased urinary sodium occurred during the first 30 min. This effect was not observed in patients without sodium wastage; a marked reduction of fractional sodium excretion was observed in patient V .
Renal sodium loss was not explained by a defect of aldosterone secretion, since plasma aldosterone increased under A I1 infusion, in spite of hypokalemia. The increased urinary sodium excretion observed in spite of high plasma aldosterone in patienr II could be possibly explained by the latent effect of aldosterone. Nevertheless, it is in keeping with sodium escape to aldosterone (24) , which was observed when these patients were on a sodium-restricted diet. Therefore, renal sodium wastage in Bartter's syndrome cannot be explained by a hormonal imbalance and an intrarenal factor must be postulated.
The natriuretic effect of A I 1 stems from an inhibition of sodium reabsorption in the ascending limb of the loop of Henle (16) . According to the report of Munday et al. (21) , A I1 inhibits the glycoside-insensitive sodium pump (pump 11) but not the enzyme Na-K-ATPase (19) . Furthermore, chloride participates in sodium reabsorption (23) and A I1 can inhibit this chloride-dependent sodium reabsor~tion (22) . In Bartter's syndrome. there is also a \ , defect of s o d i u i reabsorption in the ascending limb of the loop of Henle (8) . A deficient activity of Na-K-ATPase was recently described (15) , but the defect of sodium transport was not recognized in all patients (12) . Thus, the natriuretic effect of A I1 in Bartter's syndrome may depend on Na-K-ATPase activity and could be explained as following (Fig. 5) : when pump I1 is inhibited by A 11, an increased compensatory activity of Na-K-ATPase would result, especially under aldosterone stimulation (IS), and no renal sodium wastage would be observed. O n the contrary, if the activity of Na-K-ATPase is low, pump I could not compensate the inhibition of pump I1 by A I1 and renal wastage would occur. This possibility is supported by the dissociation between sodium and potassium urinary excretion which is observed only when patient IV is on a sodium-restricted diet (Fig. 2) . In this case, the increased urinary potassium excretion could be explained by the reactional aldosterone effect. However, our hypothesis needs further study, especially in keeping with the role of chloride in active transport of sodium (22, 23) and the effect of prostaglandins. These results show that: (1) A I1 stimulates aldosterone secretion in these patients in spite of hypokalemia; (2) the feedback effect of A I1 on P R A exists even in patients with renal sodium wastage or when a patient is on a salt-restricted diet; (3) no normalization of P R A levels is observed and it is in keeping with the persistent hypokalemia; (4) the natriuretic effect of A I1 is found only in patients who show an escape to aldosterone during salt-restricted diet.
Renin secretion is not autonomous in Bartter's syndrome. P R A levels were reduced by A I 1 infusions but did not return to normal. This could be explained by the persistent hypokalemia. The natriuretic effect of A I 1 was only observed in the salt-craving patients. Therefore, the presence of renal sodium wastage depends on an intrarenal factor.
